AstraZeneca CEO doubles down on U.S. amid rumors of listing shift

Core Viewpoint - AstraZeneca is committed to the U.S. market and is considering shifting its listing to the U.S. to better serve domestic patient needs [1][2] Group 1: U.S. Market Commitment - The CEO stated that the U.S. is expected to represent 50% of AstraZeneca's revenue by 2030, with thousands of employees across the country [2] - The company aims to achieve $80 billion in revenue by the end of the decade, with the U.S. being a key market for this ambition [2] Group 2: Investment and Manufacturing - AstraZeneca plans to invest $50 billion in enhancing its U.S. manufacturing and research capabilities, reflecting a broader trend among pharmaceutical firms to increase domestic spending [3] - The company is rapidly transferring manufacturing to the U.S. to become self-sufficient and meet local patient needs [1][3] Group 3: Biopharmaceutical Innovation - The CEO emphasized the U.S. leadership in biopharmaceutical innovation, criticizing Europe's lack of development in this sector [4] - The company has engaged with the Trump administration to discuss growth plans, indicating a strategic alignment with U.S. policy [4]